|
Synonyms: CFZ-533 | iscalimab (proposed INN) | NVP-CFZ533 | OM11-62MF
Compound class:
Antibody
Comment: CFZ533 is an anti-CD40 monoclonal antibody that is designed exhibit no agonist activity and is non-depleting (no ADCC activity for an improved safety profile, particularly in non-oncologic indications). It is claimed in Novartis' patent WO2012065950 [1] as mAb1 (based on peptide sequence alignments between the INN record for iscalimab and patented sequences retrieved from a BLAST search). Blocking CD40-mediated inflammatory responses is a well advanced mechanism being expoited for potential to treat autoimmune and inflammatory disorders and/or for preventing/reducing graft rejection following organ transplant.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| CFZ533 is an anti-CD40 mAb that is being evaluated in clinical trials as a therapy for some autoimmune conditions and for preventing/reducing solid organ transplant rejection. It blocks CD40-CD40L signalling capacity [1]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Graves' disease |
Disease Ontology:
DOID:12361 |
Phase 2 clinical candidate for Graves' disease- see NCT02713256 | |
| Myasthenia gravis |
Disease Ontology:
DOID:437 OMIM: 254200 Orphanet: ORPHA589 |
Phase 2 clinical candidate for moderate to severe Myasthenia gravis- see NCT02565576 | |
| Sjögren's syndrome |
Orphanet:
ORPHA378 |
Phase 2 clinical candidate for primary Sjögren's syndrome- see NCT02291029 | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 1 clinical candidate for RA- see completed trial NCT02089087 | |
